Artielle ImmunoTherapeutics Initiates Clinical Trial For MS

Artielle ImmunoTherapeutics announced that they have initiated a Phase I clinical trial to evaluate RTL1000 in MS. RTL1000 is a novel protein drug that targets pathogenic T-cells thought to be responsible for triggering and sustaining MS.

The trial is currently open for enrollment and is a multi-center, double-blind, placebo controlled, single dose Phase I study to be conducted with 30 MS patients in the United States. The clinical trial is designed to assess the safety and pharmacokinetic properties of RTL1000. The study will be conducted at research centers located in New Haven, Connecticut; Indianapolis, Indiana; Kansas City, Kansas; Baltimore, Maryland; Portland, Oregon and Seattle, Washington. Clinical trial information can be obtained here.

They've been at this since 2004.